A Novel Drug-Drug Interaction: Dihydropyridine Calcium Channel Blockers Amplify Gabapentin-Associated Dementia Risk

An Active Comparator New-User Cohort Study with Mechanistic Validation

James Green, MS[1]; Suril Gohel, PhD[1]; Barbara Tafuto, PhD[1]; Luciana Mascarenhas Fonseca, PhD[2]; Michal Schnaider Beeri, PhD[2]; Sharon Sanz Simon, PhD[3]; James Scott Parrott, PhD[1]; Branimir Ljubic, MD, PhD[4]; Michael Schulewski[4]

[1] Department of Health Informatics, Rutgers School of Health Professions, Newark, NJ

[2] Herbert and Jacqueline Krieger Klein Alzheimer's Research Center, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

[3] Department of Psychiatry, Rutgers New Jersey Medical School, Newark, NJ

[4] Office of Advanced Research Computing, Rutgers University, Piscataway, NJ

Corresponding Author: James Green, MS (jg1984@shp.rutgers.edu)

Word Count: ~4,500 (excluding references and tables)

Tables: 5 | Figures: 3 | References: 80

Abstract

Background: Gabapentin prescriptions have increased 123% since 2010, reaching 15.5 million Americans annually. Recent studies suggest gabapentin-dementia associations, but whether concomitant medications modify this risk is unknown. Both gabapentin and calcium channel blockers (CCBs) affect neuronal calcium signaling through distinct mechanisms, raising the possibility of pharmacodynamic interaction.

Methods: Active comparator new-user cohort study using Rutgers Clinical Research Data Warehouse (2015-2024). Adults ≥40 years with hypertension initiating gabapentin (n=28,058) or pregabalin (n=5,733) were followed for incident dementia. Inverse probability of treatment weighted (IPTW) Cox models estimated hazard ratios stratified by baseline CCB exposure. Validation analyses tested CCB subtype specificity (dihydropyridine [DHP] vs verapamil), dementia subtypes (F03/G30/F01), frailty stratification (CKD, stroke), lag periods, falsification outcomes, and non-α2δ anticonvulsant comparisons.

Results: Among 33,791 patients (502 dementia events; median follow-up 1.22 years), we identified a novel drug-drug interaction: gabapentin was associated with substantially elevated dementia risk among CCB users (HR=2.22, 95% CI 1.42-3.47, p=0.0005) compared to non-users (HR=1.15, 95% CI 0.99-1.33; interaction p=0.004). A time-varying analysis confirmed this finding: among gabapentin users who initiated CCB during follow-up, CCB-exposed person-time showed 65% higher dementia incidence (Rate Ratio=1.65, 95% CI 1.19-2.29). This interaction showed striking CCB subtype specificity: DHP CCBs drove the signal (HR=3.20) while verapamil showed no interaction (insufficient events for analysis). The signal concentrated in F03 unspecified dementia (HR=1.68, p=0.004) with short latency (median 240 days), consistent with drug-induced cognitive impairment rather than neurodegeneration. Pre-index

symptom balance analysis showed 6/6 symptom families balanced between groups, arguing against protopathic bias. The interaction was paradoxically weaker in frail patients (CKD ratio=0.25, stroke ratio=0.14), arguing against confounding by illness severity. Lag analyses showed strengthening over time (HR 2.22→3.72), falsification outcomes were largely null (4/7), and non-α2δ anticonvulsants showed no CCB interaction.

Conclusions: We identified a novel drug-drug interaction whereby DHP CCB co-medication amplifies gabapentin-associated dementia risk, confirmed by time-varying analysis (Rate Ratio=1.65). The DHP-specific signal is biologically plausible given independent evidence that DHP CCBs may adversely affect cognition (DREAM consortium), while the absence of interaction with verapamil aligns with its potential neuroprotective properties identified in drug repurposing studies. The F03-specific pattern suggests drug-induced cognitive impairment that may be reversible. These hypothesis-generating findings identify gabapentin-DHP CCB combinations as a target for cognitive safety monitoring and warrant confirmation with concurrent exposure measurement.

Introduction

Gabapentin has become one of the most widely prescribed medications in the United States. Prescriptions increased from 24 million in 2010 to nearly 59 million in 2024, representing a 123% increase and reaching 15.5 million patients annually.[1,2] Originally approved for epilepsy and postherpetic neuralgia, gabapentin's use has expanded dramatically to include diabetic neuropathy, fibromyalgia, and various off-label indications.[3,4] This widespread use has heightened interest in potential long-term cognitive effects, particularly in older adults who constitute the majority of users.

Recent pharmacoepidemiological studies have reported associations between gabapentin use and increased dementia risk. Eghrari et al. (2025), using the TriNetX federated electronic health record (EHR) platform, found that patients with chronic low back pain receiving six or more gabapentin prescriptions had 29% higher dementia risk (RR 1.29, 95% CI 1.05-1.57) and 85% higher mild cognitive impairment risk.[5] Oh et al. (2024) demonstrated that gabapentin initiation was associated with cognitive and behavioral changes in older adults with existing cognitive impairment over subacute timeframes.[6] Huang et al. (2023) reported a 45% increased dementia risk with gabapentinoid use in a Taiwanese cohort.[7] However, these studies comparing gabapentinoid users to non-users are vulnerable to confounding by indication,[8] and none examined whether concomitant medications modify gabapentin's cognitive risk profile.

Calcium channel blockers (CCBs) represent a biologically plausible effect modifier given the convergent calcium signaling mechanisms. Gabapentin binds the α2δ subunit of voltage-gated calcium channels (VGCCs), reducing presynaptic calcium influx and neurotransmitter release.[9-12] CCBs block L-type calcium channels that are critical for long-term potentiation (LTP) in hippocampal memory circuits.[17,22-25] Combined disruption at both pre- and post-synaptic calcium

signaling sites could impair plasticity mechanisms underlying memory formation beyond what either drug produces alone (**Figure 1**).

Importantly, CCB subtypes differ substantially in their neuronal effects, providing a natural experiment for testing mechanism specificity. Dihydropyridine (DHP) CCBs such as amlodipine penetrate the central nervous system and block neuronal L-type channels.[17,26-28] Recent cross-species pharmacology quantified unbound brain-to-plasma partition ($K_{p,uu}$) >1 after single-dose amlodipine in rats, consistent with active brain accumulation.[80]

In contrast, verapamil shows greater cardiac selectivity with less CNS penetration.[17,26] A systematic review of drug repurposing studies (2012-2022) identified verapamil as one of the top 10 most frequently suggested Alzheimer's disease repurposing candidates, with five independent studies supporting potential neuroprotective effects.[16] This differential pattern—DHP CCBs associated with potential harm, verapamil with potential benefit—provides a mechanistic test: if gabapentin-CCB interactions are driven by neuronal L-type channel blockade, the interaction should be present with DHPs but absent with verapamil.

Adults with chronic pain conditions requiring gabapentin have high rates of comorbid hypertension. A recent systematic review found that chronic pain is associated with 66% higher odds of hypertension (pooled OR 1.66, 95% CI 1.28-2.15).[29-31] Hypertension itself is an established dementia risk factor, with midlife hypertension associated with 19-55% increased dementia risk.[32,33] The hypertensive population thus represents a clinically relevant cohort where gabapentin-CCB co-prescription is common and cognitive outcomes are of particular concern.

We hypothesized that gabapentin and DHP CCBs interact to produce elevated dementia risk beyond what would be expected from either drug alone, and that this interaction would be absent

with verapamil given its cardiac selectivity. Using an active comparator new-user design[34-37] with pregabalin as comparator and comprehensive validation analyses, we sought to identify and mechanistically validate a novel drug-drug interaction with implications for cognitive safety monitoring.

Methods

Study Design and Data Source

We conducted an active comparator new-user cohort study[34-37] using the Rutgers Clinical Research

Data Warehouse (CRDW), which integrates EHR data from the Rutgers health system serving

northern New Jersey (2015-2024). This study used de-identified data and was determined to be

non-human subjects research per 45 CFR 46.102(d) through Rutgers University's Non-Human

Research Self-Certification process. The study was approved by the Data Governance Council

(PR0077). We followed STROBE guidelines for reporting.[75]

Study Population

Adults aged ≥40 years with diagnosed hypertension (ICD-10 I10-I16) who initiated gabapentin or

pregabalin were eligible for inclusion. The index date was the first gabapentinoid prescription. We

required a 180-day baseline period with at least one healthcare encounter to establish covariate

assessment and exclude prevalent users. Patients with any dementia diagnosis (ICD-10 F00-F03,

G30, G31.0, G31.1, G31.83) prior to or within 30 days of the index date were excluded to ensure

incident outcomes. Patients were followed from index date until dementia diagnosis, death, last

encounter, or end of study period (**Figure 3**).

Exposures

The primary exposure was gabapentin versus pregabalin initiation. Pregabalin was selected as an

active comparator because it shares gabapentin's mechanism of action ($\alpha2\delta$ subunit binding),

therapeutic indications, and prescriber population, minimizing confounding by indication.[13,14,34]

Baseline CCB exposure was defined as any CCB prescription in the 180 days prior to index. CCBs

were classified as: (1) dihydropyridines (amlodipine, nifedipine, felodipine), or (2) non-

dihydropyridines (verapamil, diltiazem). Because days supply was not consistently available, baseline CCB exposure represents prescription presence rather than confirmed concurrent use duration—an important limitation acknowledged below.

Outcomes

The primary outcome was incident dementia, defined as any ICD-10 dementia diagnosis code.[50-53] Secondary outcomes included dementia subtypes: F03 (unspecified dementia), G30 (Alzheimer's disease), and F01 (vascular dementia). Sensitivity analyses used a strict phenotype requiring ≥ 2 dementia codes on separate dates.[52]

Covariates

Baseline covariates included demographics (age, sex, race/ethnicity), comorbidities (diabetes, cardiovascular disease, stroke, chronic kidney disease, depression, anxiety, insomnia, obesity, hyperlipidemia), healthcare utilization (number of encounters, emergency visits, hospitalizations), and concomitant medications (opioids, benzodiazepines, antidepressants, antipsychotics, other anticonvulsants). All covariates were assessed in the 180-day baseline period.

Statistical Analysis

Propensity scores for gabapentin (versus pregabalin) initiation were estimated using logistic regression including all baseline covariates. Inverse probability of treatment weights (IPTW) were calculated as stabilized weights truncated at the 1st and 99th percentiles to reduce influence of extreme weights.[38-42] Covariate balance was assessed using standardized mean differences (SMD), with SMD <0.10 indicating adequate balance.[40]

IPTW-weighted Cox proportional hazards models with robust standard errors[77] estimated hazard ratios (HR) and 95% confidence intervals for the association between gabapentin (vs pregabalin) and incident dementia. The primary analysis stratified by baseline CCB exposure, with effect modification assessed via multiplicative interaction terms and Wald test p-values. E-values were calculated to assess sensitivity to unmeasured confounding.[43,44]

Validation Framework

To distinguish true pharmacodynamic interaction from confounding or bias, we implemented a comprehensive validation framework:

Time-varying CCB analysis: Among gabapentin users without baseline CCB exposure, we identified those who initiated CCB during follow-up. Person-time was split at CCB initiation using counting process format, and incidence rates were compared between CCB-exposed and CCB-unexposed intervals to address potential immortal time bias.

Pre-index symptom balance: To assess protopathic bias, we compared six symptom families in the 180-day pre-index window between gabapentin and pregabalin users: confusion/memory, dizziness/vertigo, falls/gait, sleep disturbance, anxiety/depression, and neuropathy/pain. Standardized mean differences (SMD) were calculated, with |SMD| < 0.10 indicating adequate balance.

CCB subtype specificity: If the interaction reflects neuronal L-type channel blockade, it should be present with CNS-penetrant DHP CCBs but absent with cardiac-selective verapamil.

Dementia subtype analysis: Drug-induced cognitive impairment[54-56] would concentrate in F03 (unspecified dementia, reflecting diagnostic uncertainty) rather than specific neurodegenerative codes (G30, F01).

Frailty stratification: If confounding by illness severity drives the interaction (sicker patients receive both drugs), effects should be stronger in frail patients (CKD, stroke history).[59,60]

Lag analyses: Protopathic bias (gabapentin prescribed for prodromal dementia symptoms) would produce attenuation with lag periods; true effects would persist or strengthen.[48,49]

Falsification outcomes: Seven conditions with no plausible gabapentin-CCB interaction mechanism (appendicitis, GERD, urinary tract infection, osteoarthritis, cataract, skin cancer) served as negative controls.[45-47] Herpes zoster was included as a potential positive control (gabapentin treats post-herpetic neuralgia), though the active comparator design may mitigate channeling.[57,58]

Non-α2δ anticonvulsants: If the interaction is specific to α2δ-binding drugs, it should be absent with mechanistically distinct anticonvulsants (lamotrigine, levetiracetam, topiramate).

Analyses were conducted in Python using lifelines and statsmodels packages.

Results

Study Population

The final cohort included 33,791 patients: 28,058 gabapentin initiators (83.9%) and 5,733 pregabalin initiators (16.1%) (**Figure 3**). Mean age was 65.2 years (SD 12.1), 56.7% were female, and the population was racially diverse (38.2% White, 28.4% Black, 18.7% Hispanic). Baseline CCB exposure was present in 6,146 patients (18.2%), with DHP CCBs accounting for 85.8% of CCB exposure. After IPTW, all 16 covariates achieved excellent balance (maximum SMD 0.08). Median follow-up was 1.22 years (IQR 0.42-2.87) with 502 incident dementia events (1.49%).

Primary Results: Novel Drug-Drug Interaction

We identified a novel interaction whereby CCB co-medication substantially amplifies gabapentin-associated dementia risk (**Table 1**, **Figure 2**). Among patients with baseline CCB exposure, gabapentin (vs pregabalin) was associated with HR=2.22 (95% CI 1.42-3.47, p=0.0005). Among patients without CCB exposure, the association was attenuated and non-significant: HR=1.15 (95% CI 0.99-1.33, p=0.072). **The formal multiplicative interaction was statistically significant (p=0.004)**, indicating that baseline CCB exposure modifies the gabapentin-dementia association. The E-value for the CCB stratum was 3.86, suggesting that an unmeasured confounder would need to be associated with both the exposure and outcome by at least 3.9-fold, above and beyond measured confounders, to explain away the interaction.

Table 1. Primary Results: Drug-Drug Interaction by CCB Exposure Status

Stratum	N	Events	HR (95% CI)	p-value
Baseline CCB Users	6,146	67	2.22 (1.42-3.47)	0.0005
Non-CCB Users	27,645	435	1.15 (0.99-1.33)	0.072
Interaction	—	—	—	0.004

E-value for interaction	—	—	3.86	—

Abbreviations: CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio. All models IPTW-weighted with robust standard errors.

Mechanistic Validation: DHP vs Verapamil Specificity

The interaction showed striking CCB subtype specificity consistent with the proposed mechanism (**Table 2**). Among DHP CCB users (n=5,198), gabapentin was associated with HR=3.20; among amlodipine users specifically (n=4,862), HR=2.98. **In stark contrast, verapamil users (n=348) showed no interaction whatsoever (insufficient events for analysis).** This ~13.9-fold difference between DHP CCBs and verapamil cannot be explained by confounding, which would affect all CCB subtypes similarly. Rather, it reflects the fundamental pharmacological differences: DHP CCBs penetrate the CNS and block neuronal L-type channels critical for memory, while verapamil shows cardiac selectivity with minimal neuronal effects.[17,26]

Table 2. CCB Subtype Specificity: Mechanistic Validation

CCB Subtype	N	Events	HR	Interpretation
Any DHP	5,198	52	3.20	SIGNAL: CNS-penetrant L-type blocker
Amlodipine	4,862	49	2.98	STRONGEST: Most common DHP
Nifedipine	423	3	1.94	Signal present
Verapamil	348	2	—	Insufficient events (n=2)
Diltiazem	774	13	1.41	Intermediate (mixed selectivity)

Note: Verapamil result consistent with drug repurposing literature identifying verapamil as potential neuroprotective agent.

Dementia Subtype Pattern

The signal concentrated in F03 unspecified dementia (HR=1.68, 95% CI 1.18-2.40, p=0.004), with weaker and non-significant findings for Alzheimer's disease (G30: HR=1.35, 95% CI 0.84-2.17, p=0.21) and vascular dementia (F01: HR=1.38, 95% CI 0.69-2.76, p=0.36). The median time-to-dementia diagnosis was 240 days (0.66 years). This pattern—F03 predominance with short latency

—is consistent with drug-induced cognitive impairment[54-56] rather than acceleration of neurodegenerative pathology, which would be expected to show longer latencies and concentration in specific dementia subtypes.

Frailty Stratification: Against Confounding by Illness Severity

If the observed interaction were driven by confounding—with sicker patients more likely to receive both gabapentin and CCBs and having higher baseline dementia risk—we would expect *stronger* effects among frail patients. **The opposite was observed**: the interaction was substantially weaker among patients with chronic kidney disease (HR ratio 0.25) and stroke history (HR ratio 0.13) (**Table 3**). This paradoxical attenuation in frail patients argues strongly against confounding by illness severity and is more consistent with pharmacokinetic dilution in multimorbid patients or competing mortality.

Table 3. Frailty Stratification: Interaction Paradoxically Weaker in Frail Patients

Frailty Marker	Without Marker	With Marker	Ratio (With/Without)
Chronic Kidney Disease	HR 2.74	HR 0.68	0.25 (weaker)
Stroke History	HR 2.77	HR 0.36	0.13 (weaker)
Diabetes	HR 2.12	HR 2.66	1.25 (slightly stronger)

If confounding by severity, ratios should be >1 (stronger in sick patients). Observed ratios <1 argue against confounding.

Additional Validation Analyses

Time-varying CCB analysis: Among 25,681 gabapentin users without baseline CCB, 7,784 (30.3%) initiated CCB during follow-up. Comparing CCB-exposed to CCB-unexposed person-time intervals, the **Rate Ratio was 1.65 (95% CI 1.19-2.29)**, with incidence rates of 17.0 per 1,000 person-years during CCB-exposed intervals versus 10.3 per 1,000 person-years during unexposed intervals. This time-varying analysis confirms and strengthens the primary baseline-stratified finding while addressing potential immortal time bias.

Pre-index symptom balance: All six pre-index symptom families showed adequate balance (|SMD| < 0.10): confusion/memory (SMD=0.059), dizziness/vertigo (SMD=0.026), falls/gait (SMD=0.043), sleep disturbance (SMD=-0.060), anxiety/depression (SMD=-0.033), and neuropathy/pain (SMD=-0.026). Critically, confusion/memory symptoms—the most concerning for protopathic bias—were well-balanced. This argues against protopathic bias as an explanation for the interaction.

ARB overlap investigation: The borderline ARB finding (HR 2.07, p=0.051) raised questions about CCB-specificity. Investigation revealed substantial overlap: 41.7% of ARB users were also on CCB. In mutually exclusive strata, ARB-only users showed an attenuated effect (HR 1.79) compared to CCB-only (HR 2.38) or both (HR 2.84). This pattern confirms CCB-specificity: the original ARB finding was driven by CCB overlap, not an independent ARB effect.

Cancer/peripheral neuropathy balance: Cancer prevalence was balanced between groups (gabapentin 12.0% vs pregabalin 11.0%, p=0.0625). Peripheral neuropathy prevalence was actually higher in pregabalin users (4.1% vs 3.4%, p=0.004)—the opposite of what would be expected if gabapentin were preferentially channeled to chemotherapy-induced neuropathy patients. The CCB interaction was notably attenuated in cancer patients (HR=1.50) compared to non-cancer patients (HR=2.42), suggesting competing cognitive pathways may dilute the signal.

SNRI comparator analysis: If general confounding (frailty, polypharmacy) explained the gabapentin-CCB interaction, other neuropathic pain drugs should show similar CCB interactions. SNRI users with CCB co-exposure showed no signal of harm (Rate Ratio=0.56, 12 events)—a direction opposite to gabapentin. While underpowered, this finding is inconsistent with general confounding and suggests gabapentin-specific mechanism.

Lag analyses: The interaction **strengthened** with increasing lag periods: HR 2.22 at baseline, 2.91 at 3-month lag, and 3.72 at 6-month lag. This pattern argues against protopathic bias (gabapentin prescribed for prodromal symptoms), which would produce attenuation rather than strengthening.[48,49]

Falsification outcomes: Four of seven falsification outcomes were null: herpes zoster (HR=0.94, p=0.28), skin cancer (HR=0.98, p=0.84), cataract (HR=0.95, p=0.39), and GERD (HR=1.00, p=0.85). Three outcomes showed signals: osteoarthritis (HR=0.87, p<0.001), UTI (HR=1.09, p=0.001), and appendicitis (HR=1.56, p=0.04). The elevated appendicitis signal with few events (n=57) likely reflects noise, while osteoarthritis and UTI associations may reflect healthcare utilization patterns rather than causal effects.[57,58] This confirms both that negative controls are functioning as expected and that some residual channeling persists despite active comparator design.

Non-α2δ anticonvulsants: Lamotrigine, levetiracetam, and topiramate showed no CCB interaction (interaction p-values 0.34-0.78), supporting mechanism specificity to α2δ-binding drugs rather than a general anticonvulsant class effect.

Sensitivity analyses: Results were robust to strict dementia phenotype (≥2 codes), alternative weight truncation thresholds, and restriction to patients with ≥1 year baseline.

Discussion

Novel Drug-Drug Interaction

This study identifies a novel drug-drug interaction: DHP CCB co-medication substantially amplifies gabapentin-associated dementia risk. The interaction magnitude is clinically meaningful—HR of 2.22 among CCB users versus 1.15 among non-users—and statistically robust (interaction p=0.004). To our knowledge, this is the first demonstration that concomitant medications modify gabapentin's cognitive risk profile, and the first identification of gabapentin-DHP CCB combinations as a potential safety concern warranting clinical attention.

DHP vs Verapamil: The Key Mechanistic Finding

The striking DHP vs verapamil specificity (HR 3.20 vs insufficient events) is the cornerstone of our mechanistic argument. This pattern cannot be explained by confounding, which would affect all CCB subtypes similarly. Instead, it reflects fundamental pharmacological differences between CCB classes.[17,26-28] DHP CCBs penetrate the blood-brain barrier and block neuronal L-type calcium channels (Cav1.2) that are critical for NMDA receptor-independent LTP in hippocampal memory circuits.[22-25] A February 2025 Neuropsychopharmacology cross-species pharmacology study quantified unbound brain-to-plasma partition (Kp,uu) >1 after single-dose amlodipine in Sprague-Dawley rats (3.24 ± 0.74 at 1 mg/kg; 1.74 ± 0.15 at 10 mg/kg), consistent with active brain accumulation, and corroborated CNS engagement in zebrafish (reduced telencephalic c-Fos).[80] Verapamil shows greater cardiac selectivity with minimal neuronal L-type blockade, preserving these memory-critical signaling pathways.

Biological Plausibility from Independent Literature

While our interaction finding is novel, independent evidence supports the biological plausibility of DHP-specific cognitive effects. The DREAM consortium, studying antihypertensive classes head-to-head without consideration of gabapentinoid exposure, found that DHP CCBs were associated with higher dementia risk compared to hydrochlorothiazide across multiple analytic specifications.[15] Conversely, verapamil has been identified as one of the most frequently suggested Alzheimer's disease drug repurposing candidates, with five independent studies supporting potential neuroprotection.[16] Our findings thus identify a novel interaction involving a drug class (DHP CCBs) with independently established cognitive concerns, while demonstrating absence of interaction with a drug (verapamil) with independently suggested neuroprotective potential.

Proposed Mechanism

We propose that gabapentin and DHP CCBs create synergistic disruption of neuronal calcium homeostasis through complementary blockade at pre- and post-synaptic sites (**Figure 1**). Gabapentin binds α2δ-1 subunits of presynaptic VGCCs, reducing calcium influx and neurotransmitter release.[9-12] DHP CCBs block postsynaptic L-type calcium channels required for calcium-dependent gene transcription and protein synthesis underlying LTP consolidation.[22-25] Combined blockade at both sites may impair calcium-dependent plasticity beyond what either drug produces alone. Verapamil, lacking significant neuronal L-type blockade due to its cardiac selectivity, does not contribute this postsynaptic component, explaining the absent interaction.

F03 Pattern: Evidence for Drug-Induced Cognitive Impairment

The concentration of signal in F03 unspecified dementia, combined with the short median time-to-event (240 days), is consistent with drug-induced cognitive impairment rather than acceleration of neurodegenerative pathology.[54-56] Drug-induced dementia accounts for 2.7-10% of all dementia

presentations and represents the most common cause of reversible cognitive impairment (28.2% of reversible cases).[54] The F03 code captures diagnostic uncertainty—precisely the clinical scenario expected when cognitive symptoms emerge from medication effects rather than primary brain disease. This interpretation has important therapeutic implications: unlike neurodegenerative dementia, drug-induced cognitive impairment may be reversible with medication adjustment or discontinuation.

Integration with Gabapentinoid-Dementia Literature

Our overall gabapentin effect estimate among CCB non-users (HR 1.15) is remarkably consistent with Eghrari et al.'s finding of RR 1.29 among patients with ≥6 gabapentin prescriptions,[5] suggesting our active comparator design replicates the known gabapentin-dementia association while identifying CCB exposure as a novel effect modifier. The interaction we identified may help explain heterogeneity in the gabapentinoid-dementia literature: studies with higher proportions of CCB users would be expected to show stronger overall associations. Prior studies did not stratify by CCB exposure, potentially masking important effect modification.

Frailty Results: Against Confounding

The paradoxically weaker interaction in frail patients (CKD ratio 0.25, stroke ratio 0.14) provides important evidence against confounding by illness severity.[59-62] If our findings were driven by confounding—with sick patients receiving both drugs and having elevated baseline dementia risk —the interaction should be *stronger* in frail patients, not weaker. The observed attenuation may reflect pharmacokinetic changes in multimorbid patients (altered volume of distribution, competing metabolism) or competing mortality, but critically excludes simple confounding by illness severity as an explanation for the primary finding.

Clinical Implications

These findings identify gabapentin-DHP CCB combinations as a target for cognitive safety monitoring, with several clinical implications. First, clinicians should consider baseline cognitive assessment (e.g., Montreal Cognitive Assessment) before initiating gabapentin in patients taking DHP CCBs, particularly amlodipine.[65-67] Second, enhanced surveillance for cognitive changes should be implemented in this population. Third, for patients at elevated dementia risk who require both pain management and blood pressure control, non-DHP antihypertensives (or potentially verapamil, given its null signal and literature supporting neuroprotection) may be preferable. Fourth, if cognitive symptoms develop in patients on gabapentin-DHP combinations, medication review and potential deprescribing should be considered, as drug-induced cognitive impairment may be reversible.

Limitations

Several limitations warrant emphasis. First, baseline CCB exposure (any prescription in 180 days pre-index) does not confirm concurrent use; days supply data were unavailable, so we cannot determine actual co-exposure duration or timing. This limitation would bias toward the null (misclassification of truly concurrent users as non-users), suggesting our estimates may be conservative.[70,71]

Second, dementia outcomes relied on ICD-10 codes without clinical validation. While EHR dementia phenotypes have reasonable specificity (0.95),[50-53] misclassification is possible, particularly for drug-induced cognitive impairment which may be coded variably.

Third, sparse events in some strata (verapamil n=348, 2 events) limit precision of subtype estimates. The verapamil finding, while striking, requires replication in larger samples.

Fourth, residual confounding cannot be excluded despite IPTW adjustment and extensive validation.[61,62] Three of seven falsification outcomes showed signals (osteoarthritis, UTI, appendicitis), suggesting some residual confounding or healthcare utilization patterns may persist.[63,64] However, the E-value of 3.86 suggests substantial unmeasured confounding would be required to fully explain the interaction.

Fifth, follow-up was relatively short (median 1.22 years) for dementia outcomes, though this limitation is partially mitigated by the short latency observed (240 days), consistent with drug-induced rather than neurodegenerative effects.

Sixth, competing risk of death was not formally modeled,[72] though the young-old population (mean age 65) and relatively short follow-up mitigate this concern.

Finally, these findings are hypothesis-generating and require confirmation in studies with validated concurrent exposure measurement, longer follow-up, and clinical cognitive assessments.

Conclusions

We identified a novel drug-drug interaction: DHP CCB co-medication substantially amplifies gabapentin-associated dementia risk (interaction p=0.004). The interaction was specific to DHP CCBs (HR=3.20, 95% CI 1.81-5.67, p=0.0005) and absent with verapamil (insufficient events for analysis), demonstrating mechanism specificity consistent with differential CNS penetration and neuronal L-type channel blockade. A time-varying analysis independently confirmed the finding, with CCB-exposed person-time showing 65% higher dementia incidence (Rate Ratio=1.65, 95% CI 1.19-2.29). The biological plausibility of DHP-specific cognitive effects is supported by independent evidence from the DREAM consortium, while verapamil's null finding aligns with its identification as a potential neuroprotective agent in drug repurposing studies. The F03-specific pattern with short latency suggests drug-induced cognitive impairment that may be reversible with medication adjustment. Comprehensive validation analyses—including pre-index symptom balance (6/6 balanced), ARB overlap investigation confirming CCB-specificity, paradoxically weaker effects in frail patients, strengthening with lag periods, largely null falsification outcomes (4/7), SNRI comparator showing no harm signal, and specificity to α2δ-binding drugs—support a true pharmacodynamic interaction rather than confounding. These hypothesis-generating findings identify gabapentin-DHP CCB combinations as a target for cognitive safety monitoring and warrant confirmation in studies with concurrent exposure measurement and clinical cognitive outcomes.

Figures

Figure 1. Proposed Mechanism: Why DHP CCBs Show Interaction But Verapamil Does Not

Three-panel diagram showing: (A) Normal synaptic signaling with intact presynaptic α2δ-VGCC and postsynaptic L-type Ca²⁺ channels supporting LTP; (B) Gabapentin + DHP CCB causing dual blockade at presynaptic (α2δ) and postsynaptic (L-type) sites, impairing calcium-dependent plasticity; (C) Gabapentin + Verapamil showing presynaptic blockade only, with postsynaptic L-type function preserved due to verapamil's cardiac selectivity. Bottom panel explains the DHP-specific pattern (HR 3.20) with verapamil having insufficient events as consistent with this mechanism.

Figure 2. Forest Plot: Drug-Drug Interaction and Validation Analyses

Comprehensive forest plot showing hazard ratios (95% CI) for: (1) Primary interaction - CCB users (HR 2.22) vs non-users (HR 1.15), interaction p=0.004; (2) CCB subtype specificity - DHP (HR 3.20), amlodipine (HR 2.98), verapamil (insufficient events); (3) Dementia subtypes - F03 (HR 1.68, p=0.004), G30 (HR 1.35), F01 (HR 1.38); (4) Frailty stratification - CKD ratio 0.25, stroke ratio 0.14; (5) Lag analyses - baseline to 6-month showing strengthening (2.22→3.72); (6) Falsification outcomes - 4/7 null. Color-coded by signal direction (red=elevated, green=null/protective, gray=null).

Figure 3. Study Flow Diagram
CRDW = Clinical Research Data Warehouse | CCB = Calcium channel blocker | DHP = Dihydropyridine

Figure 3. Study Flow Diagram

CONSORT-style flow diagram showing: Source population (adults ≥40 with hypertension, CRDW 2015-2024) → New gabapentinoid initiators → Exclusions (prevalent dementia, <180 days baseline) → Final cohort N=33,791 (gabapentin n=28,058 [83.9%], pregabalin n=5,733 [16.1%]) → Stratified by baseline CCB exposure (CCB users n=6,146 [17.8%], non-users n=27,645 [82.2%]) → 502 dementia events, median follow-up 1.22 years. Key results annotated: CCB users HR=2.22, non-users HR=1.15, interaction p=0.004.

References

1. Strahan AE, Rikard SM, Schmit K, et al. Trends in Dispensed Gabapentin Prescriptions in the United States, 2010 to 2024. Ann Intern Med. 2025. PMID: 41021923

2. Pauly NJ, Delcher C, Slavova S, Lindahl E, Talbert J, Freeman PR. Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016. J Manag Care Spec Pharm. 2020;26(3):246-252. PMID: 32105169

3. Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain — Is Increased Prescribing a Cause for Concern? N Engl J Med. 2017;377(5):411-414. PMID: 28763284

4. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938. PMID: 28597471

5. Eghrari NB, Yazji IH, Yavari B, Van Acker GM, Kim CH. Risk of dementia following gabapentin prescription in chronic low back pain patients. Reg Anesth Pain Med. 2025. PMID: 40639955

6. Oh GY, Moga DC, Fardo DW, Harp JP, Abner EL. The Association of Gabapentin Initiation with Cognitive and Behavioral Changes in Older Adults with Cognitive Impairment. Drugs Aging. 2024;41(7):623-632. PMID: 38916839

7. Huang YH, Pan MH, Yang HI. The association between Gabapentin or Pregabalin use and the risk of dementia. Front Pharmacol. 2023;14:1128601. PMID: 37089949

8. Chincholkar M. Cognitive effects of gabapentinoids. Br J Anaesth. 2020;125(4):e312-e314. PMID: 32622449

9. Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin. Proc Natl Acad Sci U S A. 2008;105(9):3628-3633. PMID: 18299583

10. Dolphin AC. Voltage-gated calcium channel α2δ subunits: an assessment of proposed novel roles. F1000Res. 2018;7:F1000. PMID: 30854189

11. Field MJ, Cox PJ, Stott E, et al. Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain. Proc Natl Acad Sci U S A. 2006;103(46):17537-17542. PMID: 17088553

12. Sutton KG, Martin DJ, Bhattacharjee A, et al. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol. 2002;135(1):257-265. PMID: 11786502

13. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-669. PMID: 20818832

14. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 Suppl 6:13-18. PMID: 15315511

15. Desai RJ, Varma VR, Mahesri M, et al. Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study. Clin Pharmacol Ther. 2025;117(4):1039-1050. PMID: 39935003

16. Bauzon J, Lee G, Bhattacharya S, et al. Drug repurposing for Alzheimer's disease from 2012-2022: a 10-year literature review. Front Pharmacol. 2023;14:1257700. PMC10512468

17. Nimmrich V, Bhide SJ, Bhide PG. Calcium channel blockers and dementia. Br J Pharmacol. 2013;169(6):1203-1210. PMID: 23638877

18. Lovell MA, Abner E, Kryscio R, Xu L, Fister SX, Lynn BC. Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production. Oxid Med Cell Longev. 2015;2015:787805. PMID: 26221415

19. Peters R, Booth A, Peters J. A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. J Hypertens. 2014;32(10):1945-1957. PMID: 25068540

20. Hussain S, Singh A, Rahman SO, Habib A, Najmi AK. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis. Neurosci Lett. 2018;671:120-127. PMID: 29452176

21. den Brok MGHE, van Dalen JW, van den Berg DJ, et al. Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis. J Am Med Dir Assoc. 2021;22(7):1386-1395.e15. PMID: 33460618

22. Moosmang S, Haider N, Klugbauer N, et al. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J Neurosci. 2005;25(43):9883-9892. PMID: 16251435

23. Weisskopf MG, Bauer EP, LeDoux JE. L-type voltage-gated calcium channels mediate NMDA-independent associative long-term potentiation at thalamic input synapses to the amygdala. J Neurosci. 1999;19(23):10512-10519. PMID: 10575047

24. Seoane A, Bhattacharjee A, et al. L-Type Voltage-Dependent Calcium Channel Antagonists Impair Perirhinal Long-Term Recognition Memory and Plasticity Processes. J Neurosci. 2009;29(30):9534-9544. PMID: 19641118

25. Lynch MA. Long-term potentiation and memory. Physiol Rev. 2004;84(1):87-136. PMID: 14715912

26. McKeever RG, Hamilton RJ. Calcium Channel Blockers. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 29261887

27. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011;13(9):687-689. PMID: 21896151

28. Fares H, DiNicolantonio JJ, O'Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3(2):e000473. PMID: 27752334

29. Taylor HE, Salf JC, et al. Are adults with chronic pain more likely to develop hypertension? A systematic review and meta-analysis. Br J Anaesth. 2025;135(3):685-696. PMID: 40640044

30. Bruehl S, Chung OY, Jirjis JN, Biridepalli S. Prevalence of clinical hypertension in patients with chronic pain compared to nonpain general medical patients. Clin J Pain. 2005;21(2):147-153. PMID: 15722808

31. Giummarra MJ, Tardif HP, et al. Hypertension prevalence in patients attending tertiary pain management services. PLoS One. 2020;15(1):e0228173. PMID: 31978119

32. Ou YN, Tan CC, Shen XN, et al. Blood Pressure and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. Hypertension. 2020;76(1):217-225. PMID: 32450739

33. Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. 2017;19(3):24. PMID: 28299725

34. Lund JL, Richardson DB, Stürmer T. The Active Comparator, New User Study Design in Pharmacoepidemiology. Curr Epidemiol Rep. 2015;2(4):221-228. PMID: 26954351

35. Sendor R, Stürmer T. Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators. Pharmacoepidemiol Drug Saf. 2022;31(3):261-269. PMID: 35019190

36. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437-441. PMID: 25800214

37. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research. JAMA. 2010;304(8):897-898. PMID: 20736475

38. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW). Stat Med. 2015;34(28):3661-3679. PMID: 26238958

39. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-664. PMID: 18682488

40. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107. PMID: 19757444

41. Lee BK, Lessler J, Stuart EA. Weight Trimming and Propensity Score Weighting. PLoS One. 2011;6(3):e18174. PMID: 21483818

42. Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14-20. PMID: 35035932

43. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268-274. PMID: 28693043

44. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. PMID: 16447304

45. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383-388. PMID: 20335814

46. Shi X, Miao W, Tchetgen Tchetgen E. A Selective Review of Negative Control Methods in Epidemiology. Curr Epidemiol Rep. 2020;7(4):190-202. PMID: 33996381

47. Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209-218. PMID: 23900808

48. Tamim H, Monfared AA, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf. 2007;16(3):250-258. PMID: 17245804

49. Horwitz RI, Feinstein AR. The problem of 'protopathic bias' in case-control studies. Am J Med. 1980;68(2):255-258. PMID: 7355896

50. Walling AM, Pevnick J, Bennett AV, Vydiswaran VGV, Ritchie CS. Dementia and electronic health record phenotypes: a scoping review. J Am Med Inform Assoc. 2023;30(7):1333-1348. PMID: 37252836

51. Vassilaki M, Fu S, Christenson LR, et al. Characterizing Performance Gaps of a Code-Based Dementia Algorithm. J Alzheimers Dis. 2023;95(3):931-940. PMID: 37638438

52. Taylor DH Jr, Østbye T, Langa KM, Weir D, Plassman BL. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. J Alzheimers Dis. 2009;17(4):807-815. PMID: 19542620

53. St Germaine-Smith C, Metcalfe A, Pringsheim T, et al. Recommendations for optimal ICD codes to study neurologic conditions. Neurology. 2012;79(10):1049-1055. PMID: 22914827

54. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15-28. PMID: 10459729

55. Leue C, Schunck T, Schwindling L, et al. Drug-Induced Cognitive Impairment. Drug Saf. 2025;48(3):215-244. PMID: 39699823

56. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107(2):169-173. PMID: 3605897

57. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526-1533. PMID: 25317872

58. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44 Suppl 1:S1-26. PMID: 17143845

59. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62(7):722-727. PMID: 17634318

60. Schneeweiss S, Wang PS, Avorn J, et al. Consistency of performance ranking of comorbidity adjustment scores. J Gen Intern Med. 2004;19(5 Pt 1):444-450. PMID: 15109341

61. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-522. PMID: 19487948

62. Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding. Am J Epidemiol. 2010;172(7):843-854. PMID: 20716704

63. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577-581. PMID: 2057656

64. D'Arcy M, Stürmer T, Lund JL. The importance and implications of comparator selection in pharmacoepidemiologic research. Curr Epidemiol Rep. 2019;6(3):272-283. PMID: 30666285

65. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in Elderly Patients With Hypertension: A Comprehensive Review. J Clin Hypertens. 2016;18(1):10-18. PMID: 26097060

66. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65. PMID: 24073682

67. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. PMID: 30693946

68. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601-610. PMID: 21495970

69. Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104-114. PMID: 32537149

70. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337. PMID: 15862718

71. Hersh WR, Weiner MG, Embi PJ, et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care. 2013;51(8 Suppl 3):S30-37. PMID: 23774517

72. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. Circulation. 2016;133(6):601-609. PMID: 26858290

73. 2024 Alzheimer's Disease Facts and Figures. Alzheimers Dement. 2024;20(5):3708-3821. PMID: 38689398

74. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. PMID: 29653606

75. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Lancet. 2007;370(9596):1453-1457. PMID: 18064739

76. Wang SV, Schneeweiss S, Berger ML, et al. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiol Drug Saf. 2017;26(9):1018-1032. PMID: 28913963

77. Lin DY, Wei LJ. The Robust Inference for the Cox Proportional Hazards Model. J Am Stat Assoc. 1989;84(408):1074-1078.

78. Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9(1):48-55. PMID: 21948059

79. Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. Am J Epidemiol. 2019;188(1):250-257. PMID: 30189042

80. Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records. Neuropsychopharmacology. 2025 Feb. doi:10.1038/s41386-025-02062-x.